Structures by: Heffeter P.
Total: 26
(OC-6-44)-Diamminedichloridomethoxido[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethylcarbamato]platinum(IV)
C8H16Cl2N4O5Pt
Chem. Sci. (2017) 8, 3 2241
a=12.2584(7)Å b=10.9135(6)Å c=21.9058(13)Å
α=90° β=104.6597(18)° γ=90°
(OC-6-44)-Acetatodiamminedichlorido[2-(2,5-dioxopyrrolidin-1-yl)ethyl)carbamato]platinum(IV)
C9H18Cl2N4O6Pt,H2O
Chem. Sci. (2017) 8, 3 2241
a=27.345(5)Å b=10.1753(11)Å c=12.3345(13)Å
α=90° β=101.328(5)° γ=90°
(OC-6-22)-((1R,2R)-diaminocyclohexane)bis(oxalato)platinum(IV)
C10H14N2O8Pt,2(C3H7NO)
Journal of medicinal chemistry (2014) 57, 15 6751-6764
a=8.9059(5)Å b=11.2218(6)Å c=22.0760(11)Å
α=90.00° β=90.00° γ=90.00°
(OC-6-22)-ethane-1,2-diamine(3-methylmalonato)platinum(IV)
C10H16,N2O8Pt,C3H7NO,C3H6O,H2O
Journal of medicinal chemistry (2014) 57, 15 6751-6764
a=13.8623(4)Å b=8.6180(2)Å c=18.7397(5)Å
α=90.00° β=97.8410(10)° γ=90.00°
(OC-6-54)-Dichlorido(N,N-dimethyl-ethane-1,2-diamine)aquamethoxidoplatinum(IV) trifluoroacetate
C5H17Cl2N2O2Pt,C2F3O2
Journal of medicinal chemistry (2012) 55, 24 11052-11061
a=6.1836(2)Å b=8.0658(3)Å c=15.5374(7)Å
α=102.217(3)° β=92.750(3)° γ=108.655(2)°
3-Aminopyridine-2-carbaldehyde thiosemicarbazone
C7H9N5S
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=18.5732(8)Å b=5.5273(2)Å c=17.2799(7)Å
α=90.00° β=90.00° γ=90.00°
Pyridine-2-carbaldehyde N,N-dimethylthiosemicarbazone
C9H12N4S
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=7.3747(2)Å b=7.4532(2)Å c=9.6324(3)Å
α=97.192(2)° β=109.630(2)° γ=95.020(2)°
C14H16GaN10S2,C2H6O,NO3
C14H16GaN10S2,C2H6O,NO3
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=9.3441(7)Å b=9.7491(10)Å c=12.9501(13)Å
α=102.437(6)° β=95.239(5)° γ=96.569(5)°
[Bis(3-aminopyridine-2-carbaldehyde thiosemicarbazonato)- N,N,S-iron(III)] nitrate hydrate
2(C14H16FeN10S2),NO6,NO3,4(H2O)
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=9.2033(4)Å b=23.0998(11)Å c=21.2104(8)Å
α=90.00° β=92.473(3)° γ=90.00°
9-Nitro-6-(alpha-picolylamino)-7,12-dihydroindolo[3,2-d][1]benzazepine
C22H17N5O2
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=10.8951(10)Å b=20.050(2)Å c=8.6412(9)Å
α=90.00° β=90.160(4)° γ=90.00°
(hapto^6^-p-Cymene)[9-pyridin-kappaN-2-yl-(E)-methylidene)amino-kappaN-7,12- dihydroindolo[3,2-d][1]benzazepin-6(5H)-one]chloroosmium(II) chloride acetone solvate
C35H36Cl2N4O2Os
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=9.876(2)Å b=9.6263(19)Å c=17.460(4)Å
α=90.00° β=104.32(3)° γ=90.00°
(hapto^6^-p-Cymene){9-nitro-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chlororuthenium(II) chloride diethanol solvate
C36H43Cl2N5O4Ru
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=12.2485(4)Å b=12.6418(5)Å c=14.3132(5)Å
α=95.421(2)° β=108.122(2)° γ=118.054(2)°
(hapto^6^-p-Cymene){9-nitro-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chlororuthenium(II) chloride diethanol water solvate
C36H45Cl2N5O5Ru
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=10.771(2)Å b=25.040(5)Å c=13.238(3)Å
α=90.00° β=91.84(3)° γ=90.00°
(hapto^6^-p-Cymene){9-bromo-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chloroosmium(II) chloride ethanol water solvate
C130H133Br4Cl8N16O3.5Os4
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=13.8319(5)Å b=14.1376(5)Å c=18.3912(6)Å
α=98.511(2)° β=107.338(2)° γ=102.012(2)°
(hapto^6^-p-Cymene){9-nitro-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chloroosmium(II) chloride ethanol water solvate
C35.9H42.95Cl2N5O4.08Os
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=12.2836(4)Å b=12.6756(4)Å c=14.2592(6)Å
α=95.491(2)° β=107.998(2)° γ=118.072(2)°
(hapto^6^-p-Cymene){6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chloroosmium(II) chloride water solvate
C32H32.5Cl2N4O0.25Os
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=13.9580(7)Å b=14.0949(7)Å c=18.3531(9)Å
α=96.749(3)° β=108.022(3)° γ=102.050(3)°
(OC-6-33)-Dichlorido(ethane-1,2-diamine)[bis(2-(2,5-dioxo-2,5- dihydro-1H-pyrrol-1-yl)ethylcarbamoyloxy)platinum(IV)]
C16H22Cl2N6O8Pt
Chemical communications (Cambridge, England) (2013) 49, 22 2249-2251
a=26.9636(16)Å b=7.7770(4)Å c=11.3395(6)Å
α=90.00° β=106.782(2)° γ=90.00°
Fac,cis-[RuII(CO)3Cl2(MBI)]
C11H8Cl2N2O3Ru
Dalton transactions (Cambridge, England : 2003) (2017) 46, 9 3025-3040
a=7.4138(9)Å b=20.935(3)Å c=9.771(1)Å
α=90.00° β=109.94(1)° γ=90.00°
Cis,trans-[RuII(CO)2Cl2(MBI)2]
C18H16Cl2N4O2Ru
Dalton transactions (Cambridge, England : 2003) (2017) 46, 9 3025-3040
a=12.818(5)Å b=11.653(5)Å c=13.918(5)Å
α=90.00° β=105.766(5)° γ=90.00°
Fac,cis-[RuII(CO)3Cl2(DMBI)]
C12H10Cl2N2O3Ru
Dalton transactions (Cambridge, England : 2003) (2017) 46, 9 3025-3040
a=10.4194(3)Å b=10.4212(4)Å c=14.7120(5)Å
α=90.00° β=90.00° γ=90.00°
(OC-6-33)-Dichlorido(ethane-1,2-diamine)[bis(2-(2,5-dioxo-2,5- dihydro-1H-pyrrol-1-yl)ethylcarbamoyloxy)platinum(IV)]
C16H22Cl2N6O8Pt
Chemical communications (Cambridge, England) (2013) 49, 22 2249-2251
a=26.9636(16)Å b=7.7770(4)Å c=11.3395(6)Å
α=90.00° β=106.782(2)° γ=90.00°
(hapto^6^-p-Cymene)[9-pyridin-kappaN-2-yl-(E)-methylidene)amino-kappaN-7,12- dihydroindolo[3,2-d][1]benzazepin-6(5H)-one]chlororuthenium(II) chloride acetone solvate
C35H36Cl2N4O2Ru
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=9.872(2)Å b=9.6208(19)Å c=17.434(4)Å
α=90.00° β=104.05(3)° γ=90.00°
[(hapto^6^-p-Cymene)(6-chloro-11h-indolo[3,2-c]quinolin-2-yl)- (1-kappaN-pyridin-2-yl-methylidene)-kappaN-amine-chloridoruthenium(II)]chloride
C31H27Cl2N4Ru,Cl,4(H2O)
Organometallics (2013) 32, 3 903
a=9.8541(7)Å b=12.9200(10)Å c=13.3236(10)Å
α=107.902(5)° β=104.282(5)° γ=94.798(5)°
[(hapto^6^-p-Cymene)(11h-indolo[3,2-c]quinolin-2-yl)- (1-kappaN-pyridin-2-yl-methylidene)-kappaN-amine-chloridoruthenium(II)]chloride
C31H28ClN4Ru,CH4O,Cl,2(H2O)
Organometallics (2013) 32, 3 903
a=11.998(3)Å b=21.243(4)Å c=12.307(2)Å
α=90.00° β=90.084(7)° γ=90.00°
[(hapto^6^-p-Cymene)(5,11-dihydroindolo[3,2-c]quinolin-6-one-2-yl)- (1-kappaN-pyridin-2-yl-methylidene)-kappaN-amine-chloridoruthenium(II)]chloride
C31H28ClN4ORu,C2H6O,Cl,H2O
Organometallics (2013) 32, 3 903
a=17.7577(11)Å b=9.4186(5)Å c=18.9531(12)Å
α=90.00° β=90.097(2)° γ=90.00°
[(hapto^6^-p-Cymene)(5,11-dihydroindolo[3,2-c]quinolin-6-one-2-yl)- (1-kappaN-pyridin-2-yl-methylidene)-kappaN-amine-chloridoosmium(II)]chloride
C31H28ClN4OOs,C2H6O,H2O,Cl
Organometallics (2013) 32, 3 903
a=17.7341(18)Å b=9.5157(9)Å c=19.070(2)Å
α=90.00° β=90.096(7)° γ=90.00°